NCT05756322: An ongoing trial by Lin BioScience, Inc
This trial is ongoing. It must report results 1 year, 12 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05756322 |
|---|---|
| Title | A Phase 1/2, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety and Tolerability of LBS-007 in Patients With Relapsed or Resistant Acute Leukaemias |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | July 20, 2023 |
| Completion date | Dec. 31, 2026 |
| Required reporting date | Dec. 31, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 23, 2025 |
| Days late | None |